An observational study in Ulcerative Colitis, Healthy and Crohn Disease, sponsored by Mount Sinai Hospital, Canada. Recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Mount Sinai Hospital, Canada · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 265 studies in Colitis, Ulcerative with a site in Canada — 47 open to participants now, 84 under way, 24 of them phase 3. Colitis, Ulcerative · Canada.
Among the 265 studies in Colitis, Ulcerative with a site in Canada, this one is the 21st largest by planned enrollment of the 38 observational ones that give a count, is one of 13 that started in 2022, is one of 38 observational ones, reaches primary completion later than 37 of the 83 other live ones, and was the 211th registered.
1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.
Browse Colitis, Ulcerative studies →47 of the 265 studies in Colitis, Ulcerative with a site in Canada are open now. Recruiting first, the newest first:
Palisade Bio · Sites in Canada, United States, Czechia and 9 more countries
Ages 18–75
AbbVie · Sites in Canada, United States, Israel and 2 more countries
Ages 18–75
McMaster University · Sites in Canada
Ages 18+
Pfizer · Sites in Canada, United States, Australia and 7 more countries
Ages 2–11
Janssen Research & Development, LLC · Sites in Canada, United States, Argentina and 30 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
265 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 90 · Phase 3 86 · Phase 4 12
First in 2000; this study’s year is marked. 13 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 199 across 552 observational studies indexed under Colitis, Ulcerative.
Median enrollment 162 across the 227 interventional studies, 197 across the 38 observational. Of the 165 that completed or were terminated, 95 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
181 of 265 have an industry lead sponsor. The 10 most frequent:
Mount Sinai Hospital, Canada is the lead sponsor of 158 studies on the registry; 32 are open to participants now.
Mount Sinai Hospital, Canada has 9 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
27 of the studies in Colitis, Ulcerative with a site in Canada that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT06660693Phase 3McMaster UniversityComparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis | 2027-05 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 27 to your calendar (.ics) → With an account.
Among the 265 studies in Colitis, Ulcerative with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Objective:
To use clinical, genetic and genome analysis to better understand and define the genetic and environmental factors that contribute to IBD within affected populations.
Background:
Inflammatory bowel disease (IBD) is a chronic, and often disabling, disorder of the intestines characterized by dysregulation of mucosal immune response. Recent data suggests that the incidence and prevalence rates among all populations may be increasing due to constantly changing environmental exposures. The goal of the study is to identify susceptible genes that contribute to the pathogenesis of IBD in affected individuals.
IBD or Healthy controls (non-IBD)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Subjects with other gastrointestinal conditions not meeting the above IBD or Healthy Control criteria
Available medical records to confirm IBD diagnosis (Crohn's disease, Ulcerative colitis, IBD undetermined (IBD-U)) Any age Willing to provide blood or saliva sample
Genetic: Blood or saliva sample collection
No personal history of IBD, no family history of IBD, no history of unexplained chronic diarrhea/blood in stool/anemia/abdominal pain/weight loss Any age Willing to provide blood or saliva sample
Genetic: Blood or saliva sample collection
Blood or saliva sample \& clinical data collection
Genomics studies across populations
Whole Exome Sequencing (+/- other sequencing) is planned
Time frame: 2022-2027
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2022 (actual). Primary completion is estimated for May 2027, 60 months after the start.
Of 188 non-industry observational studies under Colitis, Ulcerative, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 119. This study's planned 60 months is above that.
Counting every sponsor, half of 271 studies reached it within 47 months; a quarter within 29 and three quarters within 90.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mount Sinai Hospital, Canada →